Bain Capital Public Equity LP Increases Stake in Haleon plc (NYSE:HLN)

Bain Capital Public Equity LP raised its stake in shares of Haleon plc (NYSE:HLN - Free Report) by 20.0% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 185,282 shares of the company's stock after purchasing an additional 30,818 shares during the quarter. Haleon comprises 1.1% of Bain Capital Public Equity LP's holdings, making the stock its 27th biggest position. Bain Capital Public Equity LP's holdings in Haleon were worth $1,768,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds have also made changes to their positions in HLN. Procyon Advisors LLC boosted its position in Haleon by 41.3% in the fourth quarter. Procyon Advisors LLC now owns 230,240 shares of the company's stock valued at $2,196,000 after buying an additional 67,329 shares during the last quarter. Bank of New York Mellon Corp boosted its holdings in shares of Haleon by 29.8% in the 4th quarter. Bank of New York Mellon Corp now owns 2,071,017 shares of the company's stock valued at $19,758,000 after acquiring an additional 475,934 shares during the last quarter. JPMorgan Chase & Co. raised its holdings in shares of Haleon by 25.3% during the third quarter. JPMorgan Chase & Co. now owns 5,084,202 shares of the company's stock worth $53,791,000 after purchasing an additional 1,026,939 shares during the last quarter. SeaCrest Wealth Management LLC acquired a new position in Haleon during the fourth quarter valued at $102,000. Finally, Douglas Lane & Associates LLC boosted its holdings in Haleon by 1.9% in the fourth quarter. Douglas Lane & Associates LLC now owns 8,624,149 shares of the company's stock valued at $82,274,000 after purchasing an additional 161,865 shares during the last quarter. 6.67% of the stock is currently owned by institutional investors and hedge funds.

Haleon Stock Up 1.9 %

Shares of NYSE:HLN traded up $0.20 during trading hours on Friday, reaching $10.77. The stock had a trading volume of 15,262,457 shares, compared to its average volume of 12,038,098. The stock has a market capitalization of $48.59 billion, a price-to-earnings ratio of 31.68, a P/E/G ratio of 2.82 and a beta of 0.24. The firm's 50 day moving average is $10.20 and its 200-day moving average is $9.83. Haleon plc has a 1 year low of $8.22 and a 1 year high of $10.85. The company has a debt-to-equity ratio of 0.44, a quick ratio of 0.58 and a current ratio of 0.84.

Haleon (NYSE:HLN - Get Free Report) last posted its earnings results on Thursday, February 27th. The company reported $0.05 EPS for the quarter. Haleon had a net margin of 10.85% and a return on equity of 14.76%. The firm had revenue of $3.54 billion for the quarter, compared to the consensus estimate of $3.38 billion. Research analysts predict that Haleon plc will post 0.43 earnings per share for the current fiscal year.

Haleon Increases Dividend

The company also recently disclosed a -- dividend, which will be paid on Thursday, June 5th. Shareholders of record on Friday, April 25th will be paid a $0.1166 dividend. The ex-dividend date of this dividend is Friday, April 25th. This represents a yield of 1.6%. This is a boost from Haleon's previous -- dividend of $0.05. Haleon's payout ratio is currently 58.97%.

Analyst Ratings Changes

Several research analysts recently weighed in on the company. Deutsche Bank Aktiengesellschaft reiterated a "hold" rating on shares of Haleon in a research report on Monday, March 3rd. Hsbc Global Res cut shares of Haleon from a "strong-buy" rating to a "hold" rating in a research note on Wednesday, March 5th. Morgan Stanley upgraded shares of Haleon from an "equal weight" rating to an "overweight" rating and set a $11.25 price target on the stock in a research report on Friday. HSBC reiterated a "hold" rating on shares of Haleon in a research report on Wednesday, March 5th. Finally, Barclays restated an "overweight" rating on shares of Haleon in a research report on Tuesday. Five equities research analysts have rated the stock with a hold rating, three have assigned a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average price target of $11.25.

Haleon Company Profile

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands.